| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2006-03-10 10:07:06 UTC |
|---|
| Update Date | 2022-03-07 02:49:11 UTC |
|---|
| HMDB ID | HMDB0001903 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Calcitriol |
|---|
| Description | Calcitriol, also known as rocaltrol or 1a,25(OH)2D3, belongs to the class of organic compounds known as vitamin d and derivatives. Vitamin D and derivatives are compounds containing a secosteroid backbone, usually secoergostane or secocholestane. Thus, calcitriol is considered to be a secosteroid lipid molecule. Calcitriol is a very hydrophobic molecule, practically insoluble (in water), and relatively neutral. Calcitriol is a potentially toxic compound. |
|---|
| Structure | C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (1alpha,3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol | ChEBI | | (1S,3R,5Z,7E)-9,10-Secocholesta-5,7,10-triene-1,3,25-triol | ChEBI | | (5Z,7E)-(1S,3R)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol | ChEBI | | 1,25-DHCC | ChEBI | | 1-alpha-25-Dihydroxyvitamin D3 | ChEBI | | 1alpha,25(OH)2D3 | ChEBI | | 1alpha,25-Dihydroxycholecalciferol | ChEBI | | 1alpha,25-Dihydroxyvitamin D3 | ChEBI | | 5-{2-[1-(5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol | ChEBI | | Calcijex | ChEBI | | Calcitriolum | ChEBI | | Decostriol | ChEBI | | Rocaltrol | ChEBI | | (1S,3R,5Z,7E)-9,10-Seco-5,7,10(19)-cholestatriene-1,3,25-triol | Kegg | | (1a,3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol | Generator | | (1Α,3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol | Generator | | 1-a-25-Dihydroxyvitamin D3 | Generator | | 1-Α-25-dihydroxyvitamin D3 | Generator | | 1a,25(OH)2D3 | Generator | | 1Α,25(OH)2D3 | Generator | | 1a,25-Dihydroxycholecalciferol | Generator | | 1Α,25-dihydroxycholecalciferol | Generator | | 1a,25-Dihydroxyvitamin D3 | Generator | | 1Α,25-dihydroxyvitamin D3 | Generator | | (3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trienetriol | HMDB | | 1,25 Dihydroxycholecalciferol | HMDB | | 1,25-Dihydroxycholecalciferol | HMDB | | 1,25-Dihydroxyvitamin D | HMDB | | 1,25-Dihydroxyvitamin D3 | HMDB | | 1-alpha,25-Dihydroxyvitamin D3 | HMDB | | 1a,25-(OH)2D3 | HMDB | | 25-Dihydroxycholecalciferol | HMDB | | Dihydroxyvitamin D3 | HMDB | | Ro 21-5535 | HMDB | | Silkis | HMDB | | Soltriol | HMDB | | Topitriol | HMDB | | Toptriol | HMDB | | 1 alpha, 25-Dihydroxy-20-epi-vitamin D3 | HMDB | | 1 alpha,25-Dihydroxycholecalciferol | HMDB | | 1,25(OH)2-20EPi-D3 | HMDB | | Bocatriol | HMDB | | Calcitriol alphapharm brand | HMDB | | Calcitriol kyramed | HMDB | | Calcitriol-nefro | HMDB | | Hoffmann-la roche brand OF calcitriol | HMDB | | KyraMed, calcitriol | HMDB | | Tirocal | HMDB | | alpha,25-Dihydroxyvitamin D3, 1 | HMDB | | 1,25-Dihydroxy-20-epi-vitamin D3 | HMDB | | 20 Epi 1alpha,25 dihydroxycholecaliferol | HMDB | | Abbott brand OF calcitriol | HMDB | | Calcitriol galderma brand | HMDB | | Calcitriol jenapharm brand | HMDB | | Calcitriol leo brand | HMDB | | Cryopharma brand OF calcitriol | HMDB | | Medice brand OF calcitriol | HMDB | | Renatriol | HMDB | | Roche brand OF calcitriol | HMDB | | 1 alpha,25 Dihydroxycholecalciferol | HMDB | | 1 alpha,25-Dihydroxyvitamin D3 | HMDB | | 20-Epi-1alpha,25-dihydroxycholecaliferol | HMDB | | Calcitriol gry brand | HMDB | | Calcitriol kyramed brand | HMDB | | Calcitriol medice brand | HMDB | | Calcitriol nefro | HMDB | | Calcitriol renacare brand | HMDB | | Calcitriol roche brand | HMDB | | D3, 1,25-Dihydroxyvitamin | HMDB | | D3, 1,25-Dihydroxy-20-epi-vitamin | HMDB | | Galderma brand OF calcitriol | HMDB | | Hoffmann la roche brand OF calcitriol | HMDB | | KyraMed brand OF calcitriol | HMDB | | Leo brand OF calcitriol | HMDB | | RenaCare brand OF calcitriol | HMDB | | Sitriol | HMDB | | 1 alpha, 25 Dihydroxy 20 epi vitamin D3 | HMDB | | 1 alpha,25 Dihydroxyvitamin D3 | HMDB | | 1,25 Dihydroxyvitamin D3 | HMDB | | 1,25 Dihydroxy 20 epi vitamin D3 | HMDB | | Alphapharm brand OF calcitriol | HMDB | | Calcitriol abbott brand | HMDB | | Calcitriol cryopharma brand | HMDB | | CalcitriolNefro | HMDB | | D3, 1 alpha,25-Dihydroxyvitamin | HMDB | | Gry brand OF calcitriol | HMDB | | Jenapharm brand OF calcitriol | HMDB | | Osteotriol | HMDB | | 1a,25-Dihydroxyvitamin D3 / 1a,25-dihydroxycholecalciferol / calcitriol | HMDB | | 1Α,25-dihydroxyvitamin D3 / 1α,25-dihydroxycholecalciferol / calcitriol | HMDB | | Calcitriol | MeSH |
|
|---|
| Chemical Formula | C27H44O3 |
|---|
| Average Molecular Weight | 416.6365 |
|---|
| Monoisotopic Molecular Weight | 416.329045274 |
|---|
| IUPAC Name | (1R,3S,5Z)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol |
|---|
| Traditional Name | calcitriol |
|---|
| CAS Registry Number | 32222-06-3 |
|---|
| SMILES | C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C |
|---|
| InChI Identifier | InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1 |
|---|
| InChI Key | GMRQFYUYWCNGIN-NKMMMXOESA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as vitamin d and derivatives. Vitamin D and derivatives are compounds containing a secosteroid backbone, usually secoergostane or secocholestane. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Steroids and steroid derivatives |
|---|
| Sub Class | Vitamin D and derivatives |
|---|
| Direct Parent | Vitamin D and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Triterpenoid
- Tertiary alcohol
- Cyclic alcohol
- Secondary alcohol
- Organic oxygen compound
- Hydrocarbon derivative
- Organooxygen compound
- Alcohol
- Aliphatic homopolycyclic compound
|
|---|
| Molecular Framework | Aliphatic homopolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 113 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 8.49 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 19.8014 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.16 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 3262.8 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 396.4 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 246.4 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 186.9 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 517.8 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 949.6 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 966.4 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 95.1 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1648.9 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 607.9 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1820.0 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 623.8 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 526.7 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 264.1 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 542.5 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.7 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Calcitriol,1TMS,isomer #1 | C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O[Si](C)(C)C)C[C@@H](O)C[C@@H]1O | 3529.7 | Semi standard non polar | 33892256 | | Calcitriol,1TMS,isomer #2 | C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O[Si](C)(C)C)C[C@@H]1O | 3374.1 | Semi standard non polar | 33892256 | | Calcitriol,1TMS,isomer #3 | C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O[Si](C)(C)C | 3376.5 | Semi standard non polar | 33892256 | | Calcitriol,2TMS,isomer #1 | C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O[Si](C)(C)C)C[C@@H](O[Si](C)(C)C)C[C@@H]1O | 3485.3 | Semi standard non polar | 33892256 | | Calcitriol,2TMS,isomer #2 | C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O[Si](C)(C)C)C[C@@H](O)C[C@@H]1O[Si](C)(C)C | 3470.9 | Semi standard non polar | 33892256 | | Calcitriol,2TMS,isomer #3 | C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O[Si](C)(C)C)C[C@@H]1O[Si](C)(C)C | 3296.4 | Semi standard non polar | 33892256 | | Calcitriol,3TMS,isomer #1 | C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O[Si](C)(C)C)C[C@@H](O[Si](C)(C)C)C[C@@H]1O[Si](C)(C)C | 3400.3 | Semi standard non polar | 33892256 | | Calcitriol,1TBDMS,isomer #1 | C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O[Si](C)(C)C(C)(C)C)C[C@@H](O)C[C@@H]1O | 3756.9 | Semi standard non polar | 33892256 | | Calcitriol,1TBDMS,isomer #2 | C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H]1O | 3584.0 | Semi standard non polar | 33892256 | | Calcitriol,1TBDMS,isomer #3 | C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O[Si](C)(C)C(C)(C)C | 3573.8 | Semi standard non polar | 33892256 | | Calcitriol,2TBDMS,isomer #1 | C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O[Si](C)(C)C(C)(C)C)C[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H]1O | 3934.9 | Semi standard non polar | 33892256 | | Calcitriol,2TBDMS,isomer #2 | C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O[Si](C)(C)C(C)(C)C)C[C@@H](O)C[C@@H]1O[Si](C)(C)C(C)(C)C | 3892.9 | Semi standard non polar | 33892256 | | Calcitriol,2TBDMS,isomer #3 | C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H]1O[Si](C)(C)C(C)(C)C | 3694.6 | Semi standard non polar | 33892256 | | Calcitriol,3TBDMS,isomer #1 | C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O[Si](C)(C)C(C)(C)C)C[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H]1O[Si](C)(C)C(C)(C)C | 4050.3 | Semi standard non polar | 33892256 |
|
|---|
| General References | - Mason RS, Lissner D, Grunstein HS, Posen S: A simplified assay for dihydroxylated vitamin D metabolites in human serum: application to hyper- and hypovitaminosis D. Clin Chem. 1980 Mar;26(3):444-50. [PubMed:6892691 ]
- Shepard RM, Horst RL, Hamstra AJ, DeLuca HF: Determination of vitamin D and its metabolites in plasma from normal and anephric man. Biochem J. 1979 Jul 15;182(1):55-69. [PubMed:227368 ]
- Mason RS, Frankel T, Chan YL, Lissner D, Posen S: Vitamin D conversion by sarcoid lymph node homogenate. Ann Intern Med. 1984 Jan;100(1):59-61. [PubMed:6546329 ]
- Mallette LE: Case report: hypoparathyroidism with menses-associated hypocalcemia. Am J Med Sci. 1992 Jul;304(1):32-7. [PubMed:1642251 ]
- Ott SM, Chesnut CH 3rd: Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med. 1989 Feb 15;110(4):267-74. [PubMed:2913914 ]
- Bhan I, Shah A, Holmes J, Isakova T, Gutierrez O, Burnett SM, Juppner H, Wolf M: Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'? Kidney Int. 2006 Oct;70(8):1486-94. Epub 2006 Aug 30. [PubMed:16941023 ]
- Josephson MA, Schumm LP, Chiu MY, Marshall C, Thistlethwaite JR, Sprague SM: Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation. 2004 Oct 27;78(8):1233-6. [PubMed:15502727 ]
- Gallagher JC, Goldgar D: Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med. 1990 Nov 1;113(9):649-55. [PubMed:2221645 ]
- Lehmann B, Sauter W, Knuschke P, Dressler S, Meurer M: Demonstration of UVB-induced synthesis of 1 alpha,25-dihydroxyvitamin D3 (calcitriol) in human skin by microdialysis. Arch Dermatol Res. 2003 Apr;295(1):24-8. Epub 2003 Mar 11. [PubMed:12709817 ]
- Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D: Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res. 2005 Sep 1;65(17):7917-25. [PubMed:16140963 ]
- Kalkwarf HJ, Specker BL, Heubi JE, Vieira NE, Yergey AL: Intestinal calcium absorption of women during lactation and after weaning. Am J Clin Nutr. 1996 Apr;63(4):526-31. [PubMed:8599316 ]
|
|---|